Q2 Earnings Estimate for IRWD Issued By Zacks Research

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Analysts at Zacks Research issued their Q2 2027 EPS estimates for Ironwood Pharmaceuticals in a report released on Monday, September 8th. Zacks Research analyst Team forecasts that the biotechnology company will post earnings of $0.01 per share for the quarter. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The business had revenue of $85.24 million for the quarter, compared to analysts’ expectations of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS.

Separately, Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. One analyst has rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.94.

Ironwood Pharmaceuticals Stock Performance

Ironwood Pharmaceuticals stock opened at $1.11 on Tuesday. Ironwood Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $5.13. The stock has a market cap of $180.30 million, a PE ratio of -22.20 and a beta of 0.33. The firm’s 50-day simple moving average is $0.95 and its 200 day simple moving average is $0.98.

Institutional Trading of Ironwood Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in IRWD. Raymond James Financial Inc. bought a new stake in Ironwood Pharmaceuticals in the fourth quarter worth about $68,000. Dimensional Fund Advisors LP lifted its stake in shares of Ironwood Pharmaceuticals by 4.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 218,422 shares of the biotechnology company’s stock valued at $968,000 after buying an additional 10,149 shares in the last quarter. Hsbc Holdings PLC lifted its stake in shares of Ironwood Pharmaceuticals by 88.9% during the 4th quarter. Hsbc Holdings PLC now owns 20,886 shares of the biotechnology company’s stock valued at $91,000 after buying an additional 9,828 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Ironwood Pharmaceuticals by 7.9% during the 4th quarter. Northern Trust Corp now owns 1,625,110 shares of the biotechnology company’s stock valued at $7,199,000 after buying an additional 118,962 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Ironwood Pharmaceuticals by 29.0% during the 4th quarter. Jane Street Group LLC now owns 417,642 shares of the biotechnology company’s stock valued at $1,850,000 after buying an additional 94,004 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.